A true milestone for HIV prevention.
Twice-a-year s.c. Lenacapavir prevents nearly all new HIV infections, superior to oral PrEP.
Biggest challenge: to make this incredibly effective prevention available to the most vulnerable populations & in regions with highest HIV transmission. #PURPOSE2
Twice-a-year s.c. Lenacapavir prevents nearly all new HIV infections, superior to oral PrEP.
Biggest challenge: to make this incredibly effective prevention available to the most vulnerable populations & in regions with highest HIV transmission. #PURPOSE2
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgende...
www.nejm.org
November 27, 2024 at 10:51 PM
A true milestone for HIV prevention.
Twice-a-year s.c. Lenacapavir prevents nearly all new HIV infections, superior to oral PrEP.
Biggest challenge: to make this incredibly effective prevention available to the most vulnerable populations & in regions with highest HIV transmission. #PURPOSE2
Twice-a-year s.c. Lenacapavir prevents nearly all new HIV infections, superior to oral PrEP.
Biggest challenge: to make this incredibly effective prevention available to the most vulnerable populations & in regions with highest HIV transmission. #PURPOSE2
Exciting news, but I want to see the data from this trial and PURPOSE2. What matters most is accessibility. This shot won't do much good if it costs $26000/dose for the uninsured
June 21, 2024 at 2:56 AM
Exciting news, but I want to see the data from this trial and PURPOSE2. What matters most is accessibility. This shot won't do much good if it costs $26000/dose for the uninsured
Twice-Yearly Lenacapavir for #HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/full/10.... (subscription req for full text) #PrEP #PURPOSE2
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgende...
www.nejm.org
November 28, 2024 at 1:23 AM
Twice-Yearly Lenacapavir for #HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/full/10.... (subscription req for full text) #PrEP #PURPOSE2
#Lenacapavir for #PrEP
Applications submitted to @ema.europa.eu for EU and global use:
i-base.info/htb/50208
Together #PURPOSE1 and #PURPOSE2 results showed 99% efficacy. Len for PrEP could play a unique role in #HIVprevention globally.
#PrEPaccess
Applications submitted to @ema.europa.eu for EU and global use:
i-base.info/htb/50208
Together #PURPOSE1 and #PURPOSE2 results showed 99% efficacy. Len for PrEP could play a unique role in #HIVprevention globally.
#PrEPaccess
February 10, 2025 at 1:17 PM
#Lenacapavir for #PrEP
Applications submitted to @ema.europa.eu for EU and global use:
i-base.info/htb/50208
Together #PURPOSE1 and #PURPOSE2 results showed 99% efficacy. Len for PrEP could play a unique role in #HIVprevention globally.
#PrEPaccess
Applications submitted to @ema.europa.eu for EU and global use:
i-base.info/htb/50208
Together #PURPOSE1 and #PURPOSE2 results showed 99% efficacy. Len for PrEP could play a unique role in #HIVprevention globally.
#PrEPaccess
@docdelrio.bsky.social Congratulations to PI.Colleen F. and all research team at EmoryCFAR and all trial sites for amazing #PURPOSE2 results.
This scientific innovation has great potential to advance #HIV response through prevention. #Equity #Lenacapavir
@iasociety.bsky.social #UniteToReachAll
This scientific innovation has great potential to advance #HIV response through prevention. #Equity #Lenacapavir
@iasociety.bsky.social #UniteToReachAll
November 30, 2024 at 4:07 AM
@docdelrio.bsky.social Congratulations to PI.Colleen F. and all research team at EmoryCFAR and all trial sites for amazing #PURPOSE2 results.
This scientific innovation has great potential to advance #HIV response through prevention. #Equity #Lenacapavir
@iasociety.bsky.social #UniteToReachAll
This scientific innovation has great potential to advance #HIV response through prevention. #Equity #Lenacapavir
@iasociety.bsky.social #UniteToReachAll
Lenacapavir: annual shot might protect against HIV infection
www.technologyreview.com/2025/03/14/1...
[Dec 2024] Breakthrough of year could end HIV pandemic
mastodon.social/@persagen/11...
en.wikipedia.org/wiki/Lenacap...
#HIV #AIDS #prophylaxis #lenacapavir
#GileadScience #PURPOSE1 #PURPOSE2
www.technologyreview.com/2025/03/14/1...
[Dec 2024] Breakthrough of year could end HIV pandemic
mastodon.social/@persagen/11...
en.wikipedia.org/wiki/Lenacap...
#HIV #AIDS #prophylaxis #lenacapavir
#GileadScience #PURPOSE1 #PURPOSE2
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
www.technologyreview.com
March 14, 2025 at 7:07 PM
Lenacapavir: annual shot might protect against HIV infection
www.technologyreview.com/2025/03/14/1...
[Dec 2024] Breakthrough of year could end HIV pandemic
mastodon.social/@persagen/11...
en.wikipedia.org/wiki/Lenacap...
#HIV #AIDS #prophylaxis #lenacapavir
#GileadScience #PURPOSE1 #PURPOSE2
www.technologyreview.com/2025/03/14/1...
[Dec 2024] Breakthrough of year could end HIV pandemic
mastodon.social/@persagen/11...
en.wikipedia.org/wiki/Lenacap...
#HIV #AIDS #prophylaxis #lenacapavir
#GileadScience #PURPOSE1 #PURPOSE2
The anniversary of Adrian’s passing was a few days ago, so that deserves a double appearance from The Old Grey Whistle Test.
youtu.be/tK6BoTGt3Wg?...
youtu.be/tK6BoTGt3Wg?...
The Sound (Old Grey Whistle Test) - Sense of Purpose / New Dark Age (50p)
0:00 | Sense of Purpose2:35 | New Dark Age Reconciliation of two sources (https://www.youtube.com/watch?v=gb38SyLBZXw , https://www.youtube.com/watch?v=TatDa...
youtu.be
May 2, 2024 at 1:21 PM
The anniversary of Adrian’s passing was a few days ago, so that deserves a double appearance from The Old Grey Whistle Test.
youtu.be/tK6BoTGt3Wg?...
youtu.be/tK6BoTGt3Wg?...
Huge, fantastic news in the world of HIV prevention as Gilead today announced interim results from the PURPOSE2 study that showed dramatic efficacy of once-yearly LEN injections for #HIV prevention in cis men and gender diverse populations
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
www.gilead.com
September 12, 2024 at 4:27 PM
Huge, fantastic news in the world of HIV prevention as Gilead today announced interim results from the PURPOSE2 study that showed dramatic efficacy of once-yearly LEN injections for #HIV prevention in cis men and gender diverse populations
#PrEP #PrEP #FDA #GileadSciences #HIV #USA #preexposureprophylaxis #PrEP #HIVpreexposureprophylaxis #Yeztugo #phase3trials #PURPOSE1 #PURPOSE2 #HIVprevention #Truvada #PrEPmarket #emtricitabinetenofoviralafenamide #PrEPusers #HIVfunding #Prep4All
pharmaphorum.com/news/gileads...
pharmaphorum.com/news/gileads...
Gilead's twice-yearly PrEP drug is cleared by FDA
Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
pharmaphorum.com
July 14, 2025 at 11:40 AM
Мултиплатинената рап/рок банда 311 издаде първиа част от поредица EP-та с изпълнения на живо от 90-те. Това EP придружава предстоящото на 11 юли юбилейно преиздаване на техния едноименен албум с 3 пъти платинен сертификат. То е озаглавено „90s Throwback EP: Vol 1“ и включва следните песни: 311 -…
311 издадоха EP с концертни записи от 90-те, “90s Throwback EP: Vol 1“
Мултиплатинената рап/рок банда 311 издаде първиа част от поредица EP-та с изпълнения на живо от 90-те. Това EP придружава предстоящото на 11 юли юбилейно преиздаване на техния едноименен албум с 3 пъти платинен сертификат. То е озаглавено „90s Throwback EP: Vol 1“ и включва следните песни: 311 - “90s Throwback EP: Vol 1“ 1. Purpose2. […]
rockthenight.eu
May 31, 2025 at 6:30 AM
Мултиплатинената рап/рок банда 311 издаде първиа част от поредица EP-та с изпълнения на живо от 90-те. Това EP придружава предстоящото на 11 юли юбилейно преиздаване на техния едноименен албум с 3 пъти платинен сертификат. То е озаглавено „90s Throwback EP: Vol 1“ и включва следните песни: 311 -…
From #CROI2026 more detail about the very few breakthrough infections in PURPOSE1 and PURPOSE2 trials for 6 month LAI lenacapavir PrEP. Efficacy is incredible but patients and providers still want to know why. Research is on going with no clear answer yet. www.sfaf.org/collections/...
New research: High prevention efficacy and “breakthrough infections” on lenacapavir for PrEP - San Francisco AIDS Foundation
New research findings from the PURPOSE I and II studies, on long-acting lenacapavir injections for PrEP.
www.sfaf.org
March 8, 2026 at 4:28 PM
From #CROI2026 more detail about the very few breakthrough infections in PURPOSE1 and PURPOSE2 trials for 6 month LAI lenacapavir PrEP. Efficacy is incredible but patients and providers still want to know why. Research is on going with no clear answer yet. www.sfaf.org/collections/...
get his dirty mitts on with unfortunate asylum seekers in substandard conditions and b) a number of politically well connected slum landlords who have stuffed their fire hazard properties on Main St with Roma families who understandably hang out on the street because inside is so unfit for purpose2/
May 4, 2025 at 1:59 PM
get his dirty mitts on with unfortunate asylum seekers in substandard conditions and b) a number of politically well connected slum landlords who have stuffed their fire hazard properties on Main St with Roma families who understandably hang out on the street because inside is so unfit for purpose2/
L'essai PURPOSE1 : efficacité de 100% : aucune femme n'a contracté le #VIH
Essai PURPOSE2 : 96% d'efficacité chez les hommes
"Le lénacapavir pourrait changer la donne pour les personnes confrontées à la stigmatisation et à la discrimination dans les pays à revenu faible"
Essai PURPOSE2 : 96% d'efficacité chez les hommes
"Le lénacapavir pourrait changer la donne pour les personnes confrontées à la stigmatisation et à la discrimination dans les pays à revenu faible"
a surgeon wearing a mask and gloves is looking at the camera
ALT: a surgeon wearing a mask and gloves is looking at the camera
media.tenor.com
December 13, 2024 at 5:12 AM
L'essai PURPOSE1 : efficacité de 100% : aucune femme n'a contracté le #VIH
Essai PURPOSE2 : 96% d'efficacité chez les hommes
"Le lénacapavir pourrait changer la donne pour les personnes confrontées à la stigmatisation et à la discrimination dans les pays à revenu faible"
Essai PURPOSE2 : 96% d'efficacité chez les hommes
"Le lénacapavir pourrait changer la donne pour les personnes confrontées à la stigmatisation et à la discrimination dans les pays à revenu faible"
3️⃣ Nach positiven Ergebnissen der #PURPOSE- Studien zur #HIV- Prophylaxe #PrEP mit langwirksamem #Lenacapavir (PURPOSE1 mit cis Frauen: 100% Risikoreduktion, PURPOSE2 mit cis und trans Männern, trans Frauen, nicht-binären Personen: 96% Risikoreduktion) will der Hersteller Zulassungsanträge einreichen
September 13, 2024 at 10:05 AM
3️⃣ Nach positiven Ergebnissen der #PURPOSE- Studien zur #HIV- Prophylaxe #PrEP mit langwirksamem #Lenacapavir (PURPOSE1 mit cis Frauen: 100% Risikoreduktion, PURPOSE2 mit cis und trans Männern, trans Frauen, nicht-binären Personen: 96% Risikoreduktion) will der Hersteller Zulassungsanträge einreichen
2️⃣ Zwischen-Analyse von #PURPOSE2 zur #HIV- #PrEP: 2 HIV-Infektionen auf 2.180 Teilnehmer*innen im Lenacapavir-Arm (Inzidenz: 0,1/100 Personenjahre).
Hintergrund-Inzidenz: 2,37/100 PJ--> 96% Reduktion.
Studien-Arm mit täglicher Truvada-PrEP: 9 Infektionen/1.087 Individuen (Inzidenz: 0,93/100 PJ).
Hintergrund-Inzidenz: 2,37/100 PJ--> 96% Reduktion.
Studien-Arm mit täglicher Truvada-PrEP: 9 Infektionen/1.087 Individuen (Inzidenz: 0,93/100 PJ).
September 13, 2024 at 10:02 AM
🧵1️⃣ Zwischen-Analyse der #PURPOSE2-Studie zur #HIV- #PrEP mit langwirksamem #Lenacapivir (2 Spritzen/Jahr) mit über 3.600 cis und trans Männern, trans Frauen sowie nicht-binären Teilnehmer*innen: Gegenüber der "Hintergrund-HIV-Inzidenz" sinkt das Risiko einer HIV-Infektion um 96%.
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
www.gilead.com
September 13, 2024 at 9:56 AM
🧵1️⃣ Zwischen-Analyse der #PURPOSE2-Studie zur #HIV- #PrEP mit langwirksamem #Lenacapivir (2 Spritzen/Jahr) mit über 3.600 cis und trans Männern, trans Frauen sowie nicht-binären Teilnehmer*innen: Gegenüber der "Hintergrund-HIV-Inzidenz" sinkt das Risiko einer HIV-Infektion um 96%.
Meet College, On Purpose 2.0. Our 2019 Purpose First report demonstrated why starting college with a plan yields lifelong benefits. The new report expands that vision and puts purpose at the center of the student journey.
Read it at CompleteCollege.org/Purpose2 #HigherEd #StudentSuccess
Read it at CompleteCollege.org/Purpose2 #HigherEd #StudentSuccess
September 16, 2025 at 8:51 PM
Meet College, On Purpose 2.0. Our 2019 Purpose First report demonstrated why starting college with a plan yields lifelong benefits. The new report expands that vision and puts purpose at the center of the student journey.
Read it at CompleteCollege.org/Purpose2 #HigherEd #StudentSuccess
Read it at CompleteCollege.org/Purpose2 #HigherEd #StudentSuccess
Dive into CCA's newest report, College, On Purpose 2.0, and discover why purpose is the answer. We're tackling new challenges and showing how purpose can guide every step of the journey. Read the full report: CompleteCollege.org/Purpose2 #HigherEd #CCADoesTheWork
September 16, 2025 at 2:00 PM
Dive into CCA's newest report, College, On Purpose 2.0, and discover why purpose is the answer. We're tackling new challenges and showing how purpose can guide every step of the journey. Read the full report: CompleteCollege.org/Purpose2 #HigherEd #CCADoesTheWork